An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00235300
Recruitment Status : Completed
First Posted : October 10, 2005
Last Update Posted : March 18, 2015
Information provided by:

Brief Summary:

A multicenter clinical study comparing event-free survival at 6 months after transplant between Thymoglobulin-treated and Simulect-treated adult kidney transplant patients. Patients received Thymoglobulin or Simulect from Day 0 through Day 4. Day 0 was considered the day of the transplant procedure.

Subjects meeting all inclusion and exclusion criteria were eligible to participate in this study. The treatment assignment was random and not chosen by the subject or their physician.

Subjects were monitored during treatment with Thymoglobulin and during the transplant hospitalization. Additional subject monitoring occurred up to 12 months after transplant.

278 study subjects were enrolled at 28 transplant centers in the United States and Europe.

Condition or disease Intervention/treatment Phase
Cadaveric Donor Renal Transplantation Acute Renal Allograft Rejection Induction Therapy Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)] Drug: Simulect (basliximab) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open-Label Prospective, Randomized, Multicenter Phase II Comparative Trial of Thymoglobulin® Versus Simulect® for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients
Study Start Date : May 2000
Actual Primary Completion Date : April 2003
Actual Study Completion Date : June 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Basiliximab
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: 1 Control
Simulect (basiliximab)
Drug: Simulect (basliximab)
20 mg per day on 2 days
Experimental: 2
Thymoglobulin (anti-thymocyte globulin (rabbit))
Biological: Thymoglobulin [Anti-thymocyte Globulin (rabbit)]
1.5 mg/kg per day, for a maximum of 5 doses

Primary Outcome Measures :
  1. Freedom from acute rejection, kidney transplant loss, delayed kidney transplant function and death at 6 months after transplant. [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. 12-mo. safety & efficacy assessments including side effects and overall kidney transplant function. [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient greater than or equal to 18 years old.
  • Patient is classified as "high risk" for acute allograft rejection of DGF. Must have had at least 1 donor or 1 recipient variable for high risk.
  • Patient will be a recipient of a solitary cadaveric renal allograft.
  • Women of childbearing potential must have had a negative pregnancy test (serum or urine).
  • Man or woman agrees to practice medically acceptable contraception (i.e. barrier or pharmacologic) for a minimum of 3 months following study drug administration. In addition, women were recommended to practice contraception for 1 year following transplantation, or per local standard.
  • Patient agrees to participate in the study and sign an informed consent.
  • Patient has no known contraindication to the administration of rabbit anti-thymocyte globulin or basiliximab. Patient has no history of hypersensitivity to basiliximab.
  • Patient is dialysis-dependent at the time immediately prior to transplantation.

Exclusion Criteria:

  • Patient has received an investigational medication within the past 30 days.
  • Patient has a history of malignancy within 2 years, with the exception of adequately treated localized squamous basal cell carcinoma of the skin without evidence of recurrence.
  • Patient is currently abusing drugs or alcohol.
  • Patient is known or suspected to have an active infection or be seropositive for hepatitis B surface antigen (HBsAg), hepatitis C (HCV), or human immunodeficiency virus (HIV).
  • Patient is a multiple organ transplant recipient.
  • Patient is on any type of immunosuppression (i.e. prior transplant recipient still on immunosuppression, or patient is receiving systemic steroids for any medical condition).
  • Patient, who, in the opinion of the investigator, has significant medical or psychosocial problems or unstable disease states which would preclude enrollment. Examples of significant medical problems include, but are not limited to, morbid obesity or severe cardiac disease.
  • Kidneys that are to be implanted en bloc or from donors less than 6 years old.
  • Kidneys from donors that are known or suspected to have an active infection with or be seropositive for HBsAg, hepatitis B core antibody (HBcAb), HCV, or HIV.
  • Kidneys from donors that have received investigational therapies designed to reduce the impact of ischemia reperfusion, DGF, or other donor-related immune events.
  • Donor kidney is preserved by cold storage (with or without machine preservation) for less than 16 hours, with the exception of kidneys from non-heart-beating donors or kidneys from donors greater than 50 years old or donors with a SCr above 2.5mg/dL.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00235300

  Hide Study Locations
United States, Alabama
University of Alabama
Birmingham, Alabama, United States, 35296
United States, California
UCLA School of Medicine
Los Angeles, California, United States, 90095
California Pacific Medical Center
San Francisco, California, United States, 94115
United States, Connecticut
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
United States, Florida
Florida Hospital Medical Center and Translife
Orlando, Florida, United States, 32804
United States, Georgia
Emory University Hospital
Atlanta, Georgia, United States, 30322
Medical College of Georgia
Augusta, Georgia, United States, 30912
United States, Illinois
Rush University Transplant Program
Chicago, Illinois, United States, 60612
United States, Kentucky
University of Kentucky Medical Center
Lexington, Kentucky, United States, 40536
United States, Michigan
University of Michigan Hospital
Ann Arbor, Michigan, United States, 48109
United States, New Jersey
St. Barnabas Medical Center
Livingston, New Jersey, United States, 07039
United States, New York
Westchester Medical Center
Valhalla, New York, United States, 10595
United States, North Carolina
Carolinas Medical Center
Charlotte, North Carolina, United States, 28232
United States, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226
Hopital Saint Jacques
Besancon, France, 25000
Hopital de Bradois
Cedex, France, 54511
Centre Hospitalier Universitaire
Grenoble, France, 38043
Hopital Edouard Herriot
Lyon, France, 59003
Hopital Foch
Suresnes, France, 92151
Unicersitat Erlangen-Numberg
Erlangen, Germany, 12 91054
University Hospital Eppendorf
Hamburg, Germany, 52 20246
Hospital de Cruces
Baracaldo, Spain
Hospital Clinico Universitario
Barcelona, Spain, 08036
Hospital Reina Sofia
Cordoba, Spain, 14004
Hospital Occe de Octubre
Madrid, Spain, 28041
United Kingdom
Freeman Hospital
Newcastle upon Tyne, United Kingdom
Sponsors and Collaborators
Genzyme, a Sanofi Company
Study Director: Medical Monitor Genzyme, a Sanofi Company

Publications of Results:
Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Medical Monitor, Genzyme Corporation Identifier: NCT00235300     History of Changes
Other Study ID Numbers: SMC-101-1010
First Posted: October 10, 2005    Key Record Dates
Last Update Posted: March 18, 2015
Last Verified: March 2015

Keywords provided by Sanofi:
Anti-T cells antibodies
Cadaveric Donor Renal Transplantation
Acute Renal Allograft Rejection
Induction Therapy

Additional relevant MeSH terms:
Delayed Graft Function
Pathologic Processes
Antilymphocyte Serum
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents